Investigational drug · Phase 3
Cilta-cel
Also called: JNJ-68284528
Not approved by FDA. In 6 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Multiple Myeloma.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
6
6 still active
All registered trials
26
Any phase or sponsor naming "Cilta-cel"
First trial start
2019
Nov 7, 2019
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Cilta-cel", any sponsor or status.
- Phase 213
Conditions studied
As listed on its trial records.
- Multiple Myeloma
Approved drugs for the same conditions: Multiple myeloma · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "Cilta-cel" as an intervention, largest first.
- A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple MyelomaPivotal-lookingActive, not recruiting
Stichting European Myeloma NetworkResearch network
NCT05257083 · 759 participants · Start Oct 10, 2023 · Primary completion Jun 2033
Drug: Daratumumab; Bortezomib and 5 more · For: Multiple Myeloma
Sites: Little Rock, Arkansas; Duarte, California; San Diego, California · 106 sites in all
- A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial TherapyPivotal-lookingActive, not recruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT04923893 · 743 participants · Start Aug 19, 2021 · Primary completion Feb 14, 2029
Drug: Bortezomib; Dexamethasone and 4 more · For: Multiple Myeloma
Sites: San Francisco, California; New Haven, Connecticut; Miami, Florida · 136 sites in all
- A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple MyelomaPivotal-lookingActive, not recruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT04181827 · 419 participants · Start Jun 12, 2020 · Primary completion May 1, 2024
Drug: Cilta-cel; Pomalidomide and 3 more · For: Multiple Myeloma
Sites: Birmingham, Alabama; Phoenix, Arizona; Stanford, California · 88 sites in all
St. Olavs HospitalAcademic, hospital or other
NCT06855121 · 400 participants (planned) · Start Jan 15, 2025 · Primary completion Jan 2029
Drug: Teclistamab; Elranatamab and 3 more · For: Myeloma Multiple; Plasma Cell Leukemia; AL Amyloidosis
Sites: Arendal, Norway; Ålesund, Norway; Bergen, Norway · 23 sites in all
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT05201781 · 295 participants (planned) · Start Mar 9, 2022 · Primary completion Jul 29, 2037
Drug: Cilta-cel · For: Multiple Myeloma
Sites: Phoenix, Arizona; Duarte, California; San Francisco, California · 50 sites in all
- A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple MyelomaActive, not recruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT04133636 · 208 participants · Start Nov 7, 2019 · Primary completion Feb 26, 2027
Drug: JNJ-68284528; Lenalidomide and 3 more · For: Multiple Myeloma
Sites: San Diego, California; San Francisco, California; New Haven, Connecticut · 47 sites in all
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT03548207 · 126 participants · Start Jun 29, 2018 · Primary completion Aug 23, 2022
Drug: JNJ-68284528 · For: Multiple Myeloma
Sites: Phoenix, Arizona; Duarte, California; San Francisco, California · 21 sites in all
Nanjing Legend Biotech Co.Industry
NCT03758417 · 123 participants · Start Jan 23, 2019 · Primary completion Jul 10, 2025
Drug: LCAR-B38M CAR-T Cell · For: Multiple Myeloma
Sites: Beijing, China; Fuzhou, China; Guandong, China · 11 sites in all
Nanjing Legend Biotech Co.Industry
NCT03090659 · 100 participants (planned) · Start Oct 2, 2015 · Primary completion Dec 31, 2023
Drug: LCAR-B38M CAR-T cell injection · For: Refractory or Relapsed Multiple Myeloma
Janssen Scientific Affairs, LLCJohnson & Johnson (Janssen) (JNJ)
NCT05347485 · 86 participants · Start May 13, 2022 · Primary completion Nov 30, 2023
Drug: Cilta-cel; Lymphodepleting Therapy (Cyclophosphamide and Fludarabine) · For: Multiple Myeloma
Sites: Duarte, California; San Francisco, California; Stanford, California · 18 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Real-world healthcare resource utilization and clinical outcomes among patients with relapsed/refractory multiple myeloma receiving ciltacabtagene autoleucel after four or more prior lines of therapy in inpatient versus outpatient settings.
Janakiram M, Fan L, Ghosh S, et al. · J Med Econ 2026
- The Bottom Line: OOS Cilta-cel in MM.
Ader J, Merz M · Transplant Cell Ther 2026
- Real-world outcomes of ide-cel and cilta-cel in relapsed/refractory multiple myeloma: A nationwide, retrospective analysis in Austria.
Strassl I, Nikoloudis A, Ruesing LZ, et al. · Br J Haematol 2026
- Cilta-cel CAR T-cell expansion and neurotoxicity.
· Blood 2026
- Rapid peak cilta-cel expansion is associated with delayed neurotoxicity in multiple myeloma.
Hosoya H, Velayati A, Dima D, et al. · Blood 2026
- Cost-Effectiveness of AI-Powered Decentralized Production for Advanced Therapies in the Hospital-Generated Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma From a German Hospital Perspective: Early Health Technology Assessment Study.
Boot IWA, Weltin AL, de Graaf Y, et al. · JMIR Cancer 2026
Also in development for Multiple Myeloma
- EtentamigABBV-383, TNB-383BPhase 38 trials
AbbVie · Multiple Myeloma, Relapsed or Refractory Multiple Myeloma, Amyloid Light Chain (AL) Amyloidosis
- BMS-986348CC-92480, mezigdomidePhase 37 trials
Bristol Myers Squibb · Multiple Myeloma, Relapsed or Refractory Multiple Myeloma
- GR1803Velinotamig specified specified days., CLN-803Phase 37 trials
Genrix (Shanghai) Biopharmaceutical Co., Ltd. · Multiple Myeloma, Immune Thrombocytopenia (ITP), Warm Autoimmune Hemolytic Anemia (WAIHA)
- JNJ-79635322Ramantamig, BCMAxGPRC5DxCD3Phase 37 trials
Johnson & Johnson (Janssen) · Multiple Myeloma
- Anitocabtagene AutoleucelCART-ddBCMAPhase 34 trials
Gilead Sciences · Multiple Myeloma, Newly Diagnosed Multiple Myeloma
- CevostamabRO7187797Phase 34 trials
Roche (Genentech) · Multiple Myeloma
- IBI3003Phase 34 trials
Innovent Biologics (Suzhou) Co. Ltd. · Multiple Myeloma, Relapsed or Refractory Multiple Myeloma
- Arlocabtagene AutoleucelBMS-986393, GPRC5D CAR T cellsPhase 32 trials
Bristol Myers Squibb · Multiple Myeloma, Relapsed or Refractory Multiple Myeloma (RRMM)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Johnson & Johnson (Janssen).
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.